Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 212.63 AUD 4.95% Market Closed
Market Cap: 22.2B AUD

Pro Medicus Ltd
Investor Relations

Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments.

The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.

Show more
Loading

Earnings Calls

2024 Q3
Oct 24, 2024
Show Transcript
Previous
Next
Bankinter shows strong growth with improved margins and focused risk management.
2024 Q3
Oct 24, 2024

Bankinter reported solid third-quarter results, with a 5% growth in loans and retail deposits, while off-balance sheet products surged by 23%. The bank achieved a 7% increase in total operating income to €2,151 million, driven by a 5.5% rise in net interest income and a remarkable 14% boost in fees. Profit before taxes rose 8% year-on-year to €1,083 million. Furthermore, the bank maintained a comfortable NPL ratio of 2.2% and a strong CET1 ratio of 12.56%. Looking ahead, expectations for 2025 include continued revenue growth despite potential interest rate declines, with a net interest income target of mid-single digits.

Show Full Analysis

Management

Dr. Sam Aaron Hupert M.B.B.S., M.D.
Co-Founder, CEO, MD & Executive Director
No Bio Available
Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc.
Co-Founder, Technology Director & Executive Director
No Bio Available
Mr. Clayton James Hatch B.Comm, CPA, CPA
Chief Financial Officer
No Bio Available
Dr. Malte Westerhoff
GM of Europe & Global CTO
No Bio Available
Mr. Brad Levin
GM of North America & Global Head of Marketing
No Bio Available
Ms. Sharni L. Redenbach
People & Culture Director
No Bio Available
Mr. Sean Lambright
Global Head of Sales - Visage Imaging Inc
No Bio Available
Ms. Teresa Gschwind
Global Head of Customer Service of Visage Imaging Inc.
No Bio Available
Ms. Danny English C.A.
Financial Controller & Company Secretary
No Bio Available

Contacts

Address
VICTORIA
RICHMOND
Richmond, 450 Swan St
Contacts
+61394298800.0
www.promed.com.au